News
Lygature plays a key role in establishing ImmuneHealth-4-All, awarded €6.6 million to advance immunological research
The ImmuneHealth-4-All public–private partnership programme has been awarded €6.6 million in funding through the Health~Holland PPS programme to promote public private partnerships. Building on the national ImmuneHealthXL (IHXL) initiative, the program aims to strengthen disease-overarching immunological research in immune-mediated inflammatory diseases (IMIDs) and accelerate translation towards societal and economic impact.
Lygature has been closely involved in the IHXL initiative for multiple years and has played a central role in strategic foundations of the initiative. Drawing on this long-standing engagement, Lygature supported the development and drafting of the ImmuneHealth-4-All programme proposal and will continue to contribute to its execution as a neutral and trusted partner.
Together with the other programme partners, Lygature will ensure fair, transparent and effective programme execution. This includes organising and managing collaborative processes, supporting balanced engagement between academic, patient, health foundations and industry partners, and helping to ensure alignment with broader innovation and policy objectives.
The objectives and approach of ImmuneHealthXL and the ImmuneHealth-4-All closely align with Lygature’s mission and expertise: enabling multi-stakeholder collaboration, embedding meaningful patient and public involvement in research, and supporting the strategic sharing of knowledge and assets to maximize long-term societal and economic impact.
Tale Sliedrecht (Lygature):
“I am proud that Lygature can contribute to the creation of ImmuneHealth-4-All. This programme is the result of a true collaborative effort between academic researchers, health foundations and patient organisations, and helps us to strengthen our connections with industry partners to support translation towards impact.”
Lygature looks forward to continuing its contribution to ImmuneHealth-4-All and to supporting the translation of disease-overarching immunological research into solutions that benefit people living with IMIDs, while strengthening sustainable collaboration across the health innovation ecosystem.